The start of a new year is a time to reflect on past accomplishments and future ambitions. This recently published article in the Clinical Leader shares how the FSHD Society-Fulcrum Therapeutics partnership began, how it has evolved over time, and where we hope to go in the future. You can read the whole story here: https://lnkd.in/ekCbQnqP

Announcing... A Name Change! "MAPS PBC announced the company is #rebranding and changing its name to Lykos Therapeutics (“Lykos”), effective immediately. With Breakthrough Therapy designation given to #mdma in 2017, Lykos has requested the #fda grant Priority Review of the NDA. The FDA has 60 days to determine whether the NDA will be accepted for review and whether it will be a priority or standard review (six months or ten months, respectively). If #approved by the FDA, the U.S. Drug Enforcement Administration (“DEA”) would be required to reschedule MDMA making it available for prescription #medical use." #companyculture #medicine #medicalsciences #education #science #information #lab #therapeutic #ptsd #therapists #announcement

In this video from our National Conference, Steven Munger talks about the need for increased education on smell and taste testing. Watch the video here: https://lnkd.in/etJkNFbR Rhino Therapeutics kindly sponsored our National Conference. #SmellAndTaste #SmellAndTasteTesting #SmellAndTasteTest

🎙In our newest #RunningThroughWalls episode, Nimish Shah speaks with Mirador Therapeutics Chairman and CEO Mark McKenna about the beginning of Mirador, what he learned from his time at Prometheus, what he values in a team and more. Listen here: https://vnrk.co/3KxobCR 

EQT Life Sciences EQT Group leads Series A financing in Cell Therapy company Shinobi Therapeutics. For the non life scientists, some insights from the press release..."Cell therapies have shown remarkable promise in treating blood cancers and other intractable diseases, but manufacturing costs render these therapies inaccessible to many patients around the world. Off-the-shelf cell therapies offer a more scalable manufacturing approach, but face the additional challenge of allo-rejection, as patients’ immune systems reject donor-derived and engineered cells as foreign invaders. To overcome this immune response, patients today receive immunosuppressive drugs before treatment, which can often result in unwanted side-effects and serious complications. Shinobi is taking a different approach by creating therapies that work with, not against, the patient’s immune system"

Many #oncology manufacturers might assume that a drug’s inclusion on pathways is more important than payer coverage—but both are critical. In BioPharma Dive, MMIT’s Carolyn Zele explores how #RWD can help #pharma companies fix policy/pathway misalignment. Read the article: https://ow.ly/JMqj50PZg2i. #BPDOncologyRWD

With such brilliant panel of experts you just can't afford to miss this webinar! #ESMO #PrecisionOncology #biomarkers

Discover how we identify participants for our Decoy20 clinical trials at Indaptus Therapeutics. VP of Clinical Operations, Jeffery Nieves explains our thorough process, from collaborating with healthcare professionals across the US to conducting rigorous screenings. Learn about our dedicated approach to selecting the right patients for our studies. #ClinicalTrials #CancerResearch #PatientSafety #biotech #BladderCancer

If you wish to sequence anything, here is an unmissable opportunity to avail. Diverse genomics services! And all at 15 percent off for 150 days, in celebration of our 150 sequencing runs of #IlluminaMiseq @Mibiome miBiome Therapeutics LLP #miBiome #mibiomeTherapeutics #GenomicsForAll Services include, but not limited to: #WholeGenome #Microbiome #Transcriptome #Metagenome #Epigenome #Exome #TransplantGenomics #InfectiousDiseaseGenomics #OncologyGenomics #TuberculosisGenomics (TB) #CoronavirusGenomics (COVID) #RespiratoryDiseaseGenomics #HumanPapilommaVirusGenomics (HPV) #ReproductiveHealthGenomics #GutHealth: #miGQ #OralHealth: Microbiome #SkinHealth: Microbiome #VaginalHealth: Microbiome #InfantHealth: Microbiome If you can imagine anything more, include in comments and we will try our best to include that. Thanks, Scientifically yours, Dr. Gautam Das, Ph.D.